NVO
Novo Nordisk A/S
Price Chart
Latest Quote
$38.67
-0.46 (-1.18%)
Current Price
| Previous Close | $39.13 |
| Open | $38.58 |
| Day High | $39.02 |
| Day Low | $38.54 |
| Volume | 6,636,107 |
Stock Information
Note: Financial values converted from DKK to USD
| Quarterly Dividend / Yield | $1.80 / 4.59% |
| Shares Outstanding | 3.34B |
| Quarterly Dividend Yield | 4.59% |
| Quarterly Dividend | $1.80 |
| Total Debt | $20.85B |
| Cash Equivalents | $6.69B |
| Revenue | $49.01B |
| Net Income | $17.32B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $170.61B |
| P/E Ratio | 9.45 |
| EPS (TTM) | $4.09 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $266.38B |
| Sales | $49.01B |
| Income | $17.32B |
| Book/sh | $7.51 |
| Cash/sh | $13.48 |
| Employees | 67K |
Financial Ratios
| Quick Ratio | 0.64 |
| Current Ratio | 0.87 |
| Debt/Eq | 63.33 |
| EPS Growth TTM | -20.80% |
Returns & Margins
| ROA | 18.73% |
| ROE | 59.81% |
| Gross Margin | 81.99% |
| Operating Margin | 42.54% |
| Profit Margin | 35.35% |
Ownership
| Insider Ownership | 0.00% |
| Institutional Ownership | 9.82% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 11.24 |
| PEG | 4.37 |
| P/S | 0.52 |
| P/B | 5.15 |
Analyst Data
| Recommendation | hold |
| Target Price | $44.80 |
Technical Indicators
| SMA20 | $38.44 |
| SMA50 | $41.65 |
| SMA200 | $43.63 |
| RSI | 53.67 |
| ATR | 0.7229 |
| Shares Float | 3.17B |
| Short Float | 1.00% |
| Short Ratio | 2.34 |
| Volatility | 0.38 |
| Rel Volume | 0.61 |
Performance History
| Week | -1.73% |
| Month | -0.10% |
| Quarter | -24.07% |
| 6 Months | -4.87% |
| YTD | -22.50% |
| Year | -23.34% |
| 3 Years | -56.20% |
| 5 Years | -17.13% |
| 10 Years | +173.94% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $38.67 | 6,768,700 |
| 2026-10-26 | $39.13 | 8,036,600 |
| 2026-10-23 | $39.05 | 9,183,200 |
| 2026-10-22 | $39.43 | 8,560,700 |
| 2026-10-21 | $39.06 | 6,797,400 |
| 2026-10-20 | $39.35 | 9,412,600 |
| 2026-10-19 | $38.42 | 7,443,800 |
| 2026-10-16 | $38.83 | 10,823,100 |
| 2026-10-15 | $39.22 | 14,769,100 |
| 2026-10-14 | $38.12 | 9,363,600 |
| 2026-10-13 | $38.06 | 9,253,800 |
| 2026-10-12 | $38.58 | 8,716,600 |
| 2026-10-09 | $38.64 | 9,645,400 |
| 2026-10-08 | $38.18 | 11,808,300 |
| 2026-10-07 | $38.26 | 13,665,100 |
| 2026-10-06 | $37.53 | 13,696,500 |
| 2026-10-05 | $37.54 | 18,700,700 |
| 2026-10-02 | $37.32 | 10,261,200 |
| 2026-10-01 | $37.40 | 12,656,900 |
| 2026-09-30 | $37.91 | 21,556,000 |
| 2026-09-29 | $38.31 | 9,403,500 |
| 2026-09-28 | $38.71 | 11,428,800 |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
đ° Latest News
No news articles available at the moment. Check back later for updates on NVO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $8,784,580,906 | $6,652,839,204 | $5,344,297,069 | $4,250,931,442 |
| Cost Of Revenue | $8,784,580,906 | $6,652,839,204 | $5,344,297,069 | $4,250,931,442 |
| Total Revenue | $46,182,855,570 | $43,394,377,236 | $34,706,326,902 | $26,441,905,316 |
| Operating Revenue | $108,996,314,869 | $101,695,256,437 | $90,948,684,184 | $68,093,203,416 |
| Expenses | ||||
| Interest Expense | $628,644,143 | $245,062,133 | $80,990,046 | $56,483,833 |
| Total Expenses | $27,107,159,351 | $24,216,920,460 | $19,378,885,895 | $15,263,336,339 |
| Other Income Expense | $905,683,896 | $-157,945,533 | $264,487,790 | $-810,946,462 |
| Net Non Operating Interest Income Expense | $-475,032,025 | $-13,597,960 | $49,311,283 | $-47,817,002 |
| Total Other Finance Cost | $36,012,179 | $43,184,730 | $29,437,342 | $27,046,492 |
| Interest Expense Non Operating | $628,644,143 | $245,062,133 | $80,990,046 | $56,483,833 |
| Operating Expense | $18,322,578,444 | $17,564,081,256 | $14,034,588,826 | $11,012,404,897 |
| Other Operating Expenses | $44,828,439 | $314,247,357 | $-17,781,947 | $-154,508,686 |
| Selling And Marketing Expense | $9,609,723,040 | $9,279,636,301 | $8,479,000,381 | $6,906,119,884 |
| General And Administrative Expense | $891,936,508 | $788,382,814 | $725,473,571 | $667,495,457 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $15,306,521,068 | $15,090,447,992 | $12,504,594,203 | $8,296,996,918 |
| Net Interest Income | $-475,032,025 | $-13,597,960 | $49,311,283 | $-47,817,002 |
| Interest Income | $189,624,297 | $274,648,903 | $159,738,671 | $35,713,323 |
| Normalized Income | $14,593,842,694 | $15,213,837,744 | $12,302,939,298 | $8,926,291,372 |
| Net Income From Continuing And Discontinued Operation | $15,306,521,068 | $15,090,447,992 | $12,504,594,203 | $8,296,996,918 |
| Total Operating Income As Reported | $19,075,696,220 | $19,177,456,776 | $15,327,441,007 | $11,178,568,977 |
| Net Income Common Stockholders | $15,306,521,068 | $15,090,447,992 | $12,504,594,203 | $8,296,996,918 |
| Net Income | $15,306,521,068 | $15,090,447,992 | $12,504,594,203 | $8,296,996,918 |
| Net Income Including Noncontrolling Interests | $15,306,521,068 | $15,090,447,992 | $12,504,594,203 | $8,296,996,918 |
| Net Income Continuous Operations | $15,306,521,068 | $15,090,447,992 | $12,504,594,203 | $8,296,996,918 |
| Pretax Income | $19,506,348,090 | $19,005,913,283 | $15,641,240,080 | $10,319,805,514 |
| Earnings From Equity Interest | $-2,540,278 | $-2,540,278 | $12,103,679 | $-28,241,917 |
| Interest Income Non Operating | $189,624,297 | $274,648,903 | $159,738,671 | $35,713,323 |
| Operating Income | $19,075,696,220 | $19,177,456,776 | $15,327,441,007 | $11,178,568,977 |
| Gross Profit | $37,398,274,664 | $36,741,538,033 | $29,362,029,832 | $22,190,973,874 |
| Per Share | ||||
| Diluted EPS | $3.44 | $3.38 | $2.78 | $1.83 |
| Basic EPS | $3.45 | $3.39 | $2.79 | $1.83 |
| Other | ||||
| Tax Effect Of Unusual Items | $195,545,799 | $-32,015,503 | $50,729,206 | $-153,410,091 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $21,418,281,014 | $20,683,244,042 | $16,876,413,002 | $12,259,083,785 |
| Total Unusual Items | $908,224,174 | $-155,405,255 | $252,384,112 | $-782,704,545 |
| Total Unusual Items Excluding Goodwill | $908,224,174 | $-155,405,255 | $252,384,112 | $-782,704,545 |
| Reconciled Depreciation | $2,191,512,955 | $1,276,863,371 | $1,406,566,988 | $1,100,089,893 |
| EBITDA (Bullshit earnings) | $22,326,505,188 | $20,527,838,787 | $17,128,797,114 | $11,476,379,240 |
| EBIT | $20,134,992,233 | $19,250,975,416 | $15,722,230,126 | $10,376,289,347 |
| Diluted Average Shares | $664,611,494 | $666,897,744 | $671,649,559 | $679,091,080 |
| Basic Average Shares | $663,909,182 | $665,537,948 | $669,856,421 | $676,999,086 |
| Diluted NI Availto Com Stockholders | $15,306,521,068 | $15,090,447,992 | $12,504,594,203 | $8,296,996,918 |
| Tax Provision | $4,199,827,022 | $3,915,465,290 | $3,136,645,877 | $2,022,808,596 |
| Gain On Sale Of Security | $908,224,174 | $-155,405,255 | $252,384,112 | $-782,704,545 |
| Research And Development | $7,776,090,457 | $7,181,814,784 | $4,847,896,822 | $3,593,298,242 |
| Selling General And Administration | $10,501,659,548 | $10,068,019,115 | $9,204,473,952 | $7,573,615,341 |
| Other Gand A | $891,936,508 | $788,382,814 | $725,473,571 | $667,495,457 |
Fetched: 2026-10-27
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $9,562,503,751 | $4,881,069,866 | $6,896,855,340 | $4,863,437,347 |
| Total Assets | $81,124,830,633 | $69,578,220,172 | $46,993,054,891 | $36,050,582,359 |
| Total Non Current Assets | $55,355,501,330 | $45,402,541,875 | $26,126,014,249 | $19,883,355,262 |
| Non Current Deferred Assets | $3,533,526,990 | $3,683,104,548 | $3,045,345,289 | $2,077,648,720 |
| Non Current Deferred Taxes Assets | $3,533,526,990 | $3,683,104,548 | $3,045,345,289 | $2,077,648,720 |
| Non Current Accounts Receivable | $876,246,554 | $600,103,370 | $213,682,226 | $30,782,195 |
| Investmentin Financial Assets | $319,925,626 | $340,247,852 | $187,233,447 | $151,818,980 |
| Goodwill And Other Intangible Assets | $19,433,576,591 | $16,559,774,795 | $9,026,355,621 | $7,611,719,514 |
| Other Intangible Assets | $16,468,175,351 | $13,568,671,917 | $8,359,308,448 | $6,922,108,694 |
| Current Assets | $25,769,329,303 | $24,175,678,296 | $20,867,040,642 | $16,167,227,097 |
| Hedging Assets Current | $998,478,765 | $945,282,350 | $350,259,537 | $407,490,511 |
| Inventory | $7,415,072,095 | $6,103,989,682 | $4,753,458,243 | $3,644,253,234 |
| Receivables | $13,326,897,202 | $13,195,251,020 | $11,246,110,492 | $8,592,864,616 |
| Other Receivables | $2,014,590,049 | $2,017,728,039 | $1,205,586,153 | $897,315,921 |
| Taxes Receivable | $724,427,574 | $426,318,455 | $362,064,359 | $140,462,442 |
| Accounts Receivable | $10,587,879,579 | $10,751,204,525 | $9,678,459,980 | $7,555,086,253 |
| Allowance For Doubtful Accounts Receivable | $-296,913,694 | $-317,833,633 | $-268,074,065 | $-227,130,758 |
| Gross Accounts Receivable | $10,884,793,274 | $11,069,038,158 | $9,946,534,045 | $7,782,217,010 |
| Cash Cash Equivalents And Short Term Investments | $4,028,881,241 | $3,931,155,244 | $4,517,212,370 | $3,522,618,737 |
| Cash And Cash Equivalents | $3,954,466,032 | $2,339,297,375 | $2,150,569,647 | $1,890,714,129 |
| Cash Financial | $3,954,466,032 | $2,339,297,375 | $2,150,569,647 | $1,890,714,129 |
| Debt | ||||
| Net Debt | $14,333,445,086 | $12,008,941,096 | $1,029,260,959 | $1,285,380,774 |
| Total Debt | $19,568,809,049 | $15,359,269,198 | $4,035,456,079 | $3,852,854,904 |
| Long Term Debt And Capital Lease Obligation | $17,773,131,210 | $13,399,818,130 | $3,067,460,653 | $3,633,793,265 |
| Long Term Debt | $16,691,869,262 | $12,588,722,240 | $2,387,263,805 | $3,104,369,401 |
| Current Debt And Capital Lease Obligation | $1,795,677,838 | $1,959,451,069 | $967,995,426 | $219,061,639 |
| Current Debt | $1,596,041,857 | $1,759,516,231 | $792,566,802 | $71,725,502 |
| Other Current Borrowings | $1,457,372,552 | $894,028,502 | $724,427,574 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $52,128,750,291 | $48,137,375,511 | $31,069,843,930 | $23,575,425,498 |
| Total Non Current Liabilities Net Minority Interest | $19,902,930,347 | $15,619,722,429 | $5,718,614,535 | $5,503,587,456 |
| Tradeand Other Payables Non Current | $157,048,965 | $217,567,357 | $28,241,917 | $14,942,813 |
| Non Current Deferred Liabilities | $987,869,367 | $824,096,137 | $1,518,488,657 | $1,055,112,026 |
| Non Current Deferred Taxes Liabilities | $987,869,367 | $824,096,137 | $1,518,488,657 | $1,055,112,026 |
| Current Liabilities | $32,225,819,944 | $32,517,653,082 | $25,351,229,395 | $18,071,838,042 |
| Other Current Liabilities | $6,238,176,143 | $6,410,915,061 | $4,479,407,053 | $3,961,190,298 |
| Payables And Accrued Expenses | $24,136,079,842 | $24,104,102,222 | $4,889,587,270 | $3,388,731,132 |
| Payables | $24,136,079,842 | $24,104,102,222 | $4,889,587,270 | $3,388,731,132 |
| Total Tax Payable | $1,257,587,142 | $1,451,843,711 | $1,063,330,573 | $1,059,594,870 |
| Accounts Payable | $22,878,492,700 | $22,652,258,511 | $3,826,256,697 | $2,329,136,262 |
| Other Non Current Liabilities | - | $3,436,847 | $28,241,917 | $14,942,813 |
| Current Notes Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $28,996,080,342 | $21,440,844,661 | $15,923,210,961 | $12,475,156,861 |
| Total Equity Gross Minority Interest | $28,996,080,342 | $21,440,844,661 | $15,923,210,961 | $12,475,156,861 |
| Stockholders Equity | $28,996,080,342 | $21,440,844,661 | $15,923,210,961 | $12,475,156,861 |
| Gains Losses Not Affecting Retained Earnings | $-253,280,680 | $-210,095,951 | $190,670,294 | $365,949,490 |
| Other Equity Adjustments | $-253,280,680 | $-210,095,951 | $190,670,294 | $365,949,490 |
| Retained Earnings | $29,183,014,933 | $21,584,594,522 | $15,665,895,721 | $12,041,964,712 |
| Long Term Equity Investment | $54,690,696 | $59,771,252 | $61,265,533 | $48,862,999 |
| Other | ||||
| Treasury Shares Number | $3,215,792 | $3,535,400 | $7,727,236 | $8,995,573 |
| Ordinary Shares Number | $663,980,809 | $663,661,201 | $666,193,631 | $672,396,699 |
| Share Issued | $667,196,600 | $667,196,600 | $673,920,866 | $681,392,273 |
| Tangible Book Value | $9,562,503,751 | $4,881,069,866 | $6,896,855,340 | $4,863,437,347 |
| Invested Capital | $47,283,991,460 | $35,789,083,132 | $19,103,041,567 | $15,651,251,764 |
| Working Capital | $-6,456,490,641 | $-8,341,974,785 | $-4,484,188,753 | $-1,904,610,945 |
| Capital Lease Obligations | $1,280,897,930 | $1,011,030,728 | $855,625,472 | $676,760,001 |
| Total Capitalization | $45,687,949,604 | $34,029,566,901 | $18,310,474,766 | $15,579,526,262 |
| Treasury Stock | $298,856 | $298,856 | $747,141 | $896,569 |
| Capital Stock | $66,644,946 | $66,644,946 | $67,392,087 | $68,139,227 |
| Common Stock | $66,644,946 | $66,644,946 | $67,392,087 | $68,139,227 |
| Employee Benefits | $128,657,620 | $134,933,601 | $110,875,672 | $113,864,235 |
| Non Current Pension And Other Postretirement Benefit Plans | $128,657,620 | $134,933,601 | $110,875,672 | $113,864,235 |
| Long Term Capital Lease Obligation | $1,081,261,949 | $811,095,890 | $680,196,848 | $529,423,865 |
| Long Term Provisions | $856,223,185 | $1,043,307,204 | $993,547,636 | $685,875,117 |
| Current Capital Lease Obligation | $199,635,982 | $199,934,838 | $175,428,625 | $147,336,136 |
| Line Of Credit | $27,345,348 | $67,093,230 | $68,139,227 | $71,725,502 |
| Commercial Paper | $111,323,957 | $798,394,499 | $0 | - |
| Current Provisions | $55,886,121 | $43,184,730 | $15,014,239,646 | $10,502,854,973 |
| Investments And Advances | $374,616,322 | $400,019,104 | $248,498,980 | $200,681,979 |
| Available For Sale Securities | $319,925,626 | $340,247,852 | $187,233,447 | $151,818,980 |
| Investmentsin Associatesat Cost | $54,690,696 | $59,771,252 | $61,265,533 | $48,862,999 |
| Goodwill | $2,965,401,240 | $2,991,102,878 | $667,047,172 | $689,610,820 |
| Net PPE | $31,137,534,873 | $24,159,540,058 | $13,592,132,133 | $9,962,522,855 |
| Accumulated Depreciation | $-8,806,696,270 | $-7,829,436,299 | $-7,116,066,407 | $-6,687,655,958 |
| Gross PPE | $39,944,231,143 | $31,988,976,358 | $20,708,198,540 | $16,650,178,813 |
| Construction In Progress | $19,518,601,197 | $12,775,656,831 | $5,926,767,920 | $3,341,362,415 |
| Other Properties | $1,660,594,809 | $1,519,086,370 | $1,341,715,179 | $1,212,459,847 |
| Machinery Furniture Equipment | $8,968,676,363 | $8,523,231,107 | $6,119,231,352 | $5,610,727,425 |
| Properties | $9,796,358,775 | $9,171,002,051 | $7,320,484,089 | $6,485,629,126 |
| Inventories Adjustments Allowances | $-845,912,644 | $-557,068,069 | $-375,662,319 | $-256,269,243 |
| Finished Goods | $1,791,643,279 | $1,325,875,797 | $1,079,468,811 | $902,247,049 |
| Work In Process | $3,863,912,586 | $3,337,477,284 | $2,630,084,516 | $2,043,130,821 |
| Raw Materials | $2,605,428,875 | $1,997,704,670 | $1,419,567,235 | $955,144,607 |
| Other Short Term Investments | $74,415,209 | $1,591,857,869 | $2,366,642,723 | $1,631,904,608 |
Fetched: 2026-10-27
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $4,331,772,061 | $10,409,014,108 | $10,461,762,238 | $9,583,423,689 |
| Operating Activities | ||||
| Operating Cash Flow | $17,797,189,139 | $18,076,022,030 | $16,273,918,782 | $11,787,936,891 |
| Cash Flow From Continuing Operating Activities | $17,797,189,139 | $18,076,022,030 | $16,273,918,782 | $11,787,936,891 |
| Operating Gains Losses | - | $-1,647,743,990 | $4,821,746,899 | $20,621,082 |
| Investing Activities | ||||
| Capital Expenditure | $-13,465,417,079 | $-7,667,007,922 | $-5,812,156,544 | $-2,204,513,202 |
| Investing Cash Flow | $-11,828,431,915 | $-19,260,538,816 | $-6,558,699,482 | $-3,723,450,143 |
| Cash Flow From Continuing Investing Activities | $-11,828,431,915 | $-19,260,538,816 | $-6,558,699,482 | $-3,723,450,143 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-207,406,244 | $-3,015,609,092 | $-4,471,487,362 | $-3,599,125,939 |
| Financing Cash Flow | $-4,244,954,317 | $1,305,254,716 | $-9,437,581,835 | $-7,739,928,850 |
| Cash Flow From Continuing Financing Activities | $-4,244,954,317 | $1,305,254,716 | $-9,437,581,835 | $-7,739,928,850 |
| Cash Dividends Paid | $-7,734,848,293 | $-6,595,757,658 | $-4,746,883,406 | $-3,780,979,973 |
| Net Common Stock Issuance | $-207,406,244 | $-3,015,609,092 | $-4,471,487,362 | $-3,599,125,939 |
| Dividends Received Cfi | - | - | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-11,832,914,758 | $-946,627,204 | $-219,211,067 | $-2,035,659,415 |
| Issuance Of Debt | $15,530,214,979 | $11,863,248,669 | $0 | $1,675,836,478 |
| End Cash Position | $3,954,466,032 | $2,339,297,375 | $2,150,569,647 | $1,890,714,129 |
| Beginning Cash Position | $2,339,297,375 | $2,150,569,647 | $1,890,714,129 | $1,601,720,125 |
| Effect Of Exchange Rate Changes | $-108,634,251 | $67,989,799 | $-17,781,947 | $-35,563,895 |
| Changes In Cash | $1,723,802,908 | $120,737,929 | $277,637,466 | $324,557,898 |
| Common Stock Payments | $-207,406,244 | $-3,015,609,092 | $-4,471,487,362 | $-3,599,125,939 |
| Net Issuance Payments Of Debt | $3,697,300,221 | $10,916,621,465 | $-219,211,067 | $-359,822,937 |
| Net Long Term Debt Issuance | $3,697,300,221 | $10,916,621,465 | $-219,211,067 | $-359,822,937 |
| Long Term Debt Payments | $-11,832,914,758 | $-946,627,204 | $-219,211,067 | $-2,035,659,415 |
| Long Term Debt Issuance | $15,530,214,979 | $11,863,248,669 | $0 | $1,675,836,478 |
| Net Investment Purchase And Sale | $1,486,959,322 | $683,932,551 | $-746,542,937 | $-461,732,922 |
| Sale Of Investment | $1,594,995,860 | $3,644,701,519 | $1,239,207,482 | $992,949,924 |
| Purchase Of Investment | $-108,036,538 | $-2,960,768,968 | $-1,985,750,420 | $-1,454,682,846 |
| Net Business Purchase And Sale | $150,025,843 | $-12,277,463,445 | $0 | $-1,057,204,020 |
| Sale Of Business | $150,025,843 | $0 | $0 | - |
| Purchase Of Business | $0 | $-12,277,463,445 | $0 | $-1,057,204,020 |
| Net Intangibles Purchase And Sale | $-4,478,809,340 | $-619,379,599 | $-1,956,014,222 | $-389,559,135 |
| Purchase Of Intangibles | $-4,478,809,340 | $-619,379,599 | $-1,956,014,222 | $-389,559,135 |
| Net PPE Purchase And Sale | $-8,986,607,738 | $-7,047,628,323 | $-3,856,142,323 | $-1,814,954,067 |
| Purchase Of PPE | $-8,986,607,738 | $-7,047,628,323 | $-3,856,142,323 | $-1,814,954,067 |
| Taxes Refund Paid | $-4,783,792,154 | $-4,428,452,061 | $-3,869,740,283 | $-2,168,949,307 |
| Interest Received Cfo | $208,900,526 | $281,522,597 | $160,186,955 | $41,242,164 |
| Interest Paid Cfo | $-510,894,776 | $-91,450,016 | $-73,369,212 | $-40,644,451 |
| Change In Working Capital | $558,412,922 | $386,869,429 | $2,945,676,727 | $-827,084,700 |
| Other Non Cash Items | $-466,514,622 | $66,495,518 | $63,357,527 | $353,696,384 |
| Asset Impairment Charge | $1,093,216,199 | $1,578,259,909 | - | $120,887,357 |
| Deferred Tax | $4,199,827,022 | $3,915,465,290 | $3,136,645,877 | $2,022,808,596 |
| Deferred Income Tax | $4,199,827,022 | $3,915,465,290 | $3,136,645,877 | $2,022,808,596 |
| Depreciation Amortization Depletion | $2,191,512,955 | $1,276,863,371 | $1,406,566,988 | $1,100,089,893 |
| Depreciation And Amortization | $2,191,512,955 | $1,276,863,371 | $1,406,566,988 | $1,100,089,893 |
| Amortization Cash Flow | $975,616,261 | $375,363,463 | - | $238,935,580 |
| Amortization Of Intangibles | $975,616,261 | $375,363,463 | - | $238,935,580 |
| Depreciation | $1,215,896,694 | $901,499,908 | $1,406,566,988 | $1,100,089,893 |
| Net Income From Continuing Operations | $15,306,521,068 | $15,090,447,992 | $12,504,594,203 | $8,296,996,918 |
| Change In Other Working Capital | - | $375,064,606 | $-184,543,741 | $173,336,631 |
| Change In Other Current Liabilities | - | $1,363,083,402 | $761,934,035 | $559,757,775 |
| Change In Payables And Accrued Expense | - | $-41,839,876 | $1,133,711,222 | $769,554,870 |
| Change In Payable | - | $-41,839,876 | $1,133,711,222 | $769,554,870 |
| Change In Account Payable | - | $484,147,141 | $1,497,120,434 | $1,003,708,749 |
| Change In Inventory | - | $-1,350,531,439 | $-1,109,205,009 | $-712,323,896 |
| Change In Receivables | - | $-2,138,167,112 | $-2,431,643,959 | $-1,617,410,079 |
| Changes In Account Receivables | - | $-1,072,744,545 | $-2,123,373,727 | $-1,481,878,765 |
| Stock Based Compensation | - | $342,040,990 | $321,121,051 | $229,969,892 |
| Provisionand Write Offof Assets | - | $3,142,473,574 | $4,816,068,630 | $2,759,190,420 |
| Pension And Employee Benefit Expense | - | $-17,781,947 | $4,818,011,196 | $91,898,300 |
| Earnings Losses From Equity Investments | - | $2,540,278 | $-12,103,679 | $28,241,917 |
| Gain Loss On Investment Securities | - | $-758,945,472 | $15,839,382 | $384,329,150 |
| Net Foreign Currency Exchange Gain Loss | - | $-873,556,848 | $340,247,852 | $-483,848,285 |
| Sale Of PPE | - | - | - | $0 |
Fetched: 2026-10-27